Cart
sales@molnova.com
Platelet-Derived Growth Factor Receptor Substrate 1
CAS No. ———
Platelet-Derived Growth Factor Receptor Substrate 1( ——— )
Catalog No. M41568 CAS No. ———
Platelet-Derived Growth Factor Receptor Substrate 1; PDGF Receptor Substrate
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePlatelet-Derived Growth Factor Receptor Substrate 1
-
NoteResearch use only, not for human use.
-
Brief DescriptionPlatelet-Derived Growth Factor Receptor Substrate 1; PDGF Receptor Substrate
-
DescriptionPlatelet-Derived Growth Factor Receptor Substrate 1; PDGF Receptor Substrate
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number———
-
Formula Weight———
-
Molecular Formula———
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
SBE 13 hydrochloride
SBE13 hydrochloride is an effective and specific PLK1 inhibitor (IC50: 0.2 nM); no inhibition om Aurora A kinase, Plk2/3.
-
Crilvastatin
Crilvastatin (PMD 387) is a novel, non-competitive hydroxymethylglutaryl coenzyme A reductase inhibitor with cholesterol-lowering activity, inhibiting cholesterol uptake in rats with hereditary hypercholesterolemia.
-
Parimifasor
Parimifasor(LYC-30937-EC, LYC30937) is an orally bioavailable, enteric-coated ATPase modulator as a gut-directed therapy for the treatment of inflammatory bowel disease (IBD).
